News
Why Amgen Stock Slumped on Monday
Amgen (NASDAQ: AMGN) stock came under renewed pressure on Monday, several days after more regulators piled on to block a major acquisition announced by the company. The immediate catalyst was a
Why Amgen Stock Slumped on Monday
Amgen (NASDAQ: AMGN) stock came under renewed pressure on Monday, several days after more regulators piled on to block a major acquisition announced by the company. The immediate catalyst was a
Why Amgen Stock Slumped on Monday
Amgen (NASDAQ: AMGN) stock came under renewed pressure on Monday, several days after more regulators piled on to block a major acquisition announced by the company. The immediate catalyst was a
Why Pfizer Stock Is Tanking Today
Pfizer (NYSE: PFE) is having a rough session in early trading Monday. Specifically, the drugmaker's shares were down by 5.5% on heavy volume as of 10:24 a.m. ET Monday morning.
The big dip came
Why Pfizer Stock Is Tanking Today
Pfizer (NYSE: PFE) is having a rough session in early trading Monday. Specifically, the drugmaker's shares were down by 5.5% on heavy volume as of 10:24 a.m. ET Monday morning.
The big dip came
2 Low-Priced Stocks That Could Make You Richer
Buying low-priced growth stocks ($10 or below) can be risky. Companies with bargain-basement share prices tend to have weak balance sheets, highly uncertain outlooks, and limited financing
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
UFC: The Story of a Corporate Turnaround
Michael Thomsen is the author of Cage Kings: How an Unlikely Group of Moguls, Champions, and Hustlers Transformed the UFC Into a $10 Billion Industry.
Motley Fool host Ricky Mulvey caught up with
3 Monster Stocks in the Making to Buy Right Now
What's small today could become huge in the future. That's especially true in the high-stakes world of biopharmaceutical companies. Three Fool.com contributors identified what they believe could be
1 Phenomenal High-Yield Dividend Stock You Can Buy and Hold Forever
What's the biggest knock against many high-yield dividend stocks? Probably that either the dividend or the share price is likely to sink sooner or later. That means that you often won't want to own
Wall Street Expects Intellia Therapeutics Stock to Climb 107%. Is That Too Optimistic?
Sometimes even the professionals put the horse before the cart. For instance, Wall Street analysts are currently predicting that shares of the gene editing therapy biotech Intellia Therapeutics
Why Trupanion Stock Dropped 15.6% This Week
Trupanion's (NASDAQ: TRUP) stock price had plummeted 15.6% this week as of Friday morning at 9:45 a.m. ET, according to S&P Global Market Intelligence. Trupanion was trading at about $22 per share
Why Shares of Surmodics Jumped This Week
Shares of Surmodics (NASDAQ: SRDX) were up by 24.1% for the week as of Friday morning, according to data provided by S&P Global Market Intelligence. The medical device company's stock closed last
Why Patterson Companies Stock Was Riding High This Week
The latest earnings report published by specialty healthcare company Patterson Companies (NASDAQ: PDCO) impressed not only investors, but also pundits following the stock. On that wave of optimism
Is UnitedHealth Group Stock in Trouble?
Shares of UnitedHealth Group (NYSE: UNH) fell off a cliff last week after the company reported that it is seeing a rise in surgeries. This development will increase its costs and impact its bottom
Is UnitedHealth Group Stock in Trouble?
Shares of UnitedHealth Group (NYSE: UNH) fell off a cliff last week after the company reported that it is seeing a rise in surgeries. This development will increase its costs and impact its bottom
Is This a Sign That Biogen's Leqembi Could Obtain FDA Approval Next Month?
It was two years ago that Biogen's (NASDAQ: BIIB) stock soared to more than $400 on news that its Alzheimer's treatment, Aduhelm (aducanumab), had obtained accelerated approval from the Food and
Is This a Sign That Biogen's Leqembi Could Obtain FDA Approval Next Month?
It was two years ago that Biogen's (NASDAQ: BIIB) stock soared to more than $400 on news that its Alzheimer's treatment, Aduhelm (aducanumab), had obtained accelerated approval from the Food and
Is This a Sign That Biogen's Leqembi Could Obtain FDA Approval Next Month?
It was two years ago that Biogen's (NASDAQ: BIIB) stock soared to more than $400 on news that its Alzheimer's treatment, Aduhelm (aducanumab), had obtained accelerated approval from the Food and
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Why Dice Therapeutics Stock Bolted Higher This Week
Shares of clinical-stage biotech Dice Therapeutics (NASDAQ: DICE) jumped by 37.5% during the first three and a half days of trading this week, according to data provided by S&P Global Market
Why Dice Therapeutics Stock Bolted Higher This Week
Shares of clinical-stage biotech Dice Therapeutics (NASDAQ: DICE) jumped by 37.5% during the first three and a half days of trading this week, according to data provided by S&P Global Market
Why Roivant Sciences Stock Is Perking Up Today
Shares of U.K.-based biotech Roivant Sciences (NASDAQ: ROIV) were up by 10.2% on heavy volume as of 10:21 a.m. ET Thursday. The drugmaker's stock is jumping in response to positive long-term data
Why Roivant Sciences Stock Is Perking Up Today
Shares of U.K.-based biotech Roivant Sciences (NASDAQ: ROIV) were up by 10.2% on heavy volume as of 10:21 a.m. ET Thursday. The drugmaker's stock is jumping in response to positive long-term data
I'm Buying These 3 Resilient Stocks During a Bear Market
There is a difference of opinion about whether the economy is headed for a recession or perhaps already coming out of one, depending on what metrics are used. That can be confusing for investors